A Phase 2 interventional study of folate and methotrexate in Rheumatoid Arthritis, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-10-07.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 89th largest by enrollment, is one of 6 that started in 2005, is one of 10 in phase 2, and was the 9th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 6 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 107th largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2005, is one of 20 in phase 2, and was the 16th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase II, randomized, double-blind, multicenter study designed to evaluate the safety and efficacy of rituximab, administered at two different regimens for 2 years, in patients with moderate to severe active rheumatoid arthritis (RA) receiving stable doses of methotrexate (MTX).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rituximab: 1000 mg intravenous (IV) on Days 1 and 15 of the first cycle; 500 mg IV on Days 1 and 15 of each subsequent 6-month cycle (Months 6, 12, and 18). Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion. Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant). Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk).
Drug: folate · Drug: methotrexate · Drug: methylprednisolone · Drug: Rituximab
Rituximab: 1000 mg IV on Days 1 and 15 of each 12-month cycle (Rituximab cycles were administered at baseline and Month 12.) For the Month 6 and 18 cycles, rituximab or placebo was administered. Corticosteroids: 100 mg IV methylprednisolone prior to each rituximab infusion For the Months 6 and 18 cycles, IV saline was administered prior to each rituximab or placebo infusion. Methotrexate: 15-25 mg/wk oral or parenteral (10-14 mg/wk if intolerant). Folate: Minimum of 1 mg/day (or folinic acid 5 mg/wk).
Drug: folate · Drug: methotrexate · Drug: methylprednisolone · Drug: Placebo · Drug: Rituximab
Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
500 mg or 1000 mg IV\*2.
Number of Participants With Either an Infection or a Grade III or IV Adverse Event (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTCAE], Version 3.0)
A Grade III Adverse Event (AE) is severe; defined as considerable interference with the subject's daily activities, medical intervention/therapy required and hospitalization possible. A Grade IV AE is life-threatening; defined as extreme limitation in activity, significant medical intervention/therapy required, hospitalization probable. Because of the small sample size and the small number of subjects who completed Week 104, the analysis were limited to descriptive statistics only.
Time frame: 24 months
Change From Baseline in Disease Activity Score 28-4 C-reactive Protein (DAS28-4(CRP))
The DAS28-4(CRP) score is a measure of the subject's disease activity. DAS28-4(CRP) is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and CRP. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at 24 months was analyzed for DAS28-4 (CRP).
Time frame: Baseline, 24 months
Number of Participants With American College of Rheumatology Responses (ACR20, ACR50, and ACR70)
ACR20 response was defined as satisfying the following 3 criteria improvement from baseline: ≥ 20% in tender joint count; ≥ 20% in swollen joint count; ≥ 20% improvement from baseline in 3 of the following 5 criteria: Subject's Global Assessment of Pain Subject's Global Assessment of Disease Activity Physician's Global Assessment Subject's Self-Assessment Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) Note: The definitions of ACR50 and ACR70 are the same as ACR20, except that the 20% value in the above definition is replaced by 50% and 70% values, respectively.
Time frame: Baseline, 24 months
Number of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission
Major clinical response is an ACR70 response defined as improvement from baseline: ≥70% in tender joint count; ≥70% in swollen joint count; ≥70% in 3 of the following: Patient Pain Assessment, Patient Global Assessment, Physician Global Assessment, Patient Self-Assessed Disability, ESR or CRP for ≥169 consecutive days. Remission: ≥5 requirements fulfilled for ≥2 consecutive months: Duration of morning stiffness \<15 minutes, No fatigue, No joint pain, No joint tenderness or pain on motion, No soft tissue swelling in joints or tendon sheaths, ESR \<30 mm/hour for women and \<20 mm/hour for men.
Time frame: 24 months
Number of Participants With European League Against Rheumatism (EULAR) Response and Remission Using Disease Activity Score 28-4 (DAS28-4)C-reactive Protein (CRP)
EULAR remission = DAS28-4(CRP) \< 2.6 (Fransen et al. 2004. EULAR response categories (van Gestel et al. 1999): Good response = final DAS28-4(CRP) \< 3.2 and decreased \> 1.2 points from baseline Moderate response = final DAS28-4(CRP) ≥ 3.2 but ≤ 5.1 and decreased \> 0.6 points from baseline or final DAS28-4(CRP) \> 5.1 and decreased \> 1.2 from baseline.
Time frame: Baseline, 24 months
Change From Baseline in Short Form 36 (SF 36) Summary and Subscale Scores
The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning (PF), Role Physical (RP), Bodily Pain(BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE),Mental Health (MH). Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score.
Time frame: Baseline, 24 Months
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)
The Stanford HAQ-DI is a patient-reported questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The questionnaire was provided in a certified translation of the local languages at the participating sites and was scored based on the instructions from the Stanford University Medical Center.The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction.
Time frame: Baseline, 24 Months
Change From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F)
FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.
Time frame: Baseline, 24 Months
DAS28-4 Erythrocyte Sedimentation Rate(ESR)
The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10, where a score of less than or equal to 3.2 implies well controlled disease and greater than or equal to 5.1 implies active disease In this trial, CRP rather than ESR was used, unless the CRP value was missing at both Day 1 and screening, in which case ESR value was used.
Time frame: 24 Months
Change From Baseline in Rheumatoid Factor (RF)
Serum levels of rheumatoid factor at baseline, month 24 and change from baseline to month 24.
Time frame: Baseline, 24 Months
Change From Baseline in Cyclic Citrullinated Peptide (CCP) Antibodies/Cytokines
Because of the different laboratory methods that were used to measure anti-CCP antibody levels, no summary statistics were calculated.
Time frame: Baseline, 24 Months
Approximately 40 subjects with moderately to severely active rheumatoid arthritis were to be enrolled at six to eight study centers in the United States and were randomly assigned in a 1:1 ratio to Arm A or B. Starting 15 August 2005 to 4 February 2009 (first subject enrolled to database lock).
| Milestone | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Started | 21 | 21 |
| Safety evaluable | 21 | 20 |
| Completed | 11 | 10 |
| Not completed | 10 | 11 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Other | 1 | 1 |
A Grade III Adverse Event (AE) is severe; defined as considerable interference with the subject's daily activities, medical intervention/therapy required and hospitalization possible. A Grade IV AE is life-threatening; defined as extreme limitation in activity, significant medical intervention/therapy required, hospitalization probable. Because of the small sample size and the small number of subjects who completed Week 104, the analysis were limited to descriptive statistics only.
| Participants | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Infections | 14 | 11 |
| Adverse Events (Grade 3 or 4) | 5 | 4 |
The DAS28-4(CRP) score is a measure of the subject's disease activity. DAS28-4(CRP) is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity and CRP. DAS28 provides a number on a scale (0 to 10) indicating current disease activity. A score above 5.1 means high disease activity and a score below 3.2 indicates low disease activity. Change from baseline at 24 months was analyzed for DAS28-4 (CRP).
| Scores on a scale | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Baseline | 6.53 ± 0.70 | 6.33 ± 0.85 |
| Month 24 | 4.03 ± 1.75 | 3.77 ± 1.42 |
| Change from baseline | -2.49 ± 1.85 | -2.56 ± 1.23 |
ACR20 response was defined as satisfying the following 3 criteria improvement from baseline: ≥ 20% in tender joint count; ≥ 20% in swollen joint count; ≥ 20% improvement from baseline in 3 of the following 5 criteria: Subject's Global Assessment of Pain Subject's Global Assessment of Disease Activity Physician's Global Assessment Subject's Self-Assessment Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) Note: The definitions of ACR50 and ACR70 are the same as ACR20, except that the 20% value in the above definition is replaced by 50% and 70% values, respectively.
| Participants | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| ACR20 Responders | 7 | 6 |
| ACR50 Responders | 4 | 5 |
| ACR70 Responders | 4 | 3 |
Major clinical response is an ACR70 response defined as improvement from baseline: ≥70% in tender joint count; ≥70% in swollen joint count; ≥70% in 3 of the following: Patient Pain Assessment, Patient Global Assessment, Physician Global Assessment, Patient Self-Assessed Disability, ESR or CRP for ≥169 consecutive days. Remission: ≥5 requirements fulfilled for ≥2 consecutive months: Duration of morning stiffness \<15 minutes, No fatigue, No joint pain, No joint tenderness or pain on motion, No soft tissue swelling in joints or tendon sheaths, ESR \<30 mm/hour for women and \<20 mm/hour for men.
| Participants | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Number of Participants With American College of Rheumatology (ACR) Major Clinical Response and/or Remission | 1 | 0 |
EULAR remission = DAS28-4(CRP) \< 2.6 (Fransen et al. 2004. EULAR response categories (van Gestel et al. 1999): Good response = final DAS28-4(CRP) \< 3.2 and decreased \> 1.2 points from baseline Moderate response = final DAS28-4(CRP) ≥ 3.2 but ≤ 5.1 and decreased \> 0.6 points from baseline or final DAS28-4(CRP) \> 5.1 and decreased \> 1.2 from baseline.
| Participants | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| No Response | 0 | 0 |
| Moderate Response | 2 | 6 |
| Good Response | 5 | 4 |
| Eular Remission | 3 | 3 |
The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning (PF), Role Physical (RP), Bodily Pain(BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE),Mental Health (MH). Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score.
| Units on a Scale | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Summary Score: Mental Component Score | 7.69 ± 16.10 | 2.28 ± 10.42 |
| Summary Score: Physical Component Score | 9.88 ± 12.31 | 4.93 ± 9.83 |
| Subscale: Bodily Pain | 26.64 ± 26.64 | 8.00 ± 22.55 |
| Subscale: General Health | 13.86 ± 18.78 | 18.40 ± 23.55 |
| Subscale: Mental Health | 20.00 ± 18.17 | 2.50 ± 26.48 |
| Subscale: Physical Function | 21.62 ± 35.45 | 15.72 ± 17.54 |
| Subscale: Role Emotional | 16.67 ± 45.95 | 8.33 ± 24.85 |
| Subscale: Role Physical | 34.09 ± 31.17 | -1.25 ± 23.90 |
| Subscale: Social Functioning | 21.59 ± 35.83 | 7.50 ± 25.14 |
| Subscale: Vitality | 10.61 ± 26.03 | 8.13 ± 12.86 |
The Stanford HAQ-DI is a patient-reported questionnaire specific for RA. It consists of 20 questions referring to eight component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. The questionnaire was provided in a certified translation of the local languages at the participating sites and was scored based on the instructions from the Stanford University Medical Center.The questions are evaluated on a 4-point scale: 0=without any difficulty, 1= with some difficulty, 2= with much difficulty, and 3= unable to do. Higher scores= greater dysfunction.
| Scores on a scale | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) | -0.60 ± 0.87 | -0.45 ± 0.72 |
FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status.
| Scores on a scale | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Change From Baseline in Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F) | 9.64 ± 15.54 | 8.80 ± 12.15 |
The DAS28-4(ESR) score is a measure of the subject's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10, where a score of less than or equal to 3.2 implies well controlled disease and greater than or equal to 5.1 implies active disease In this trial, CRP rather than ESR was used, unless the CRP value was missing at both Day 1 and screening, in which case ESR value was used.
| Scores on a scale | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| DAS28-4 Erythrocyte Sedimentation Rate(ESR) | 4.25 ± 1.98 | 4.32 ± 1.39 |
Serum levels of rheumatoid factor at baseline, month 24 and change from baseline to month 24.
| IU/mL | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Baseline | 542.8 ± 1011.6 | 243.7 ± 280.2 |
| Month 24 | 43.0 ± 70.8 | 41.4 ± 34.3 |
| Change from Baseline to Month 24 | -499.8 ± 946.9 | -202.3 ± 279.1 |
Because of the different laboratory methods that were used to measure anti-CCP antibody levels, no summary statistics were calculated.
No measurements were reported for this outcome.
Collected over Duration includes safety-evaluable subjects during the 2-year treatment period; in addition Serious adverse events that occurred during safety follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: 500 mg Rituximab | — | 3/21 (14.3%) | 21/21 (100%) |
| Arm B: 1000 mg Rituximab | — | 2/20 (10%) | 14/20 (70%) |
| Event | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| DEATHCardiac disorders | 0/21 | 1/20 |
| MALIGNANT MELANOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/21 | 1/20 |
| NON-CARDIAC CHEST PAINGeneral disorders | 1/21 | 0/20 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/21 | 0/20 |
| INTRACRANIAL ANEURYSMNervous system disorders | 1/21 | 0/20 |
| Event | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 3/21 | 7/20 |
| SinusitisInfections and infestations | 6/21 | 1/20 |
| NauseaGastrointestinal disorders | 5/21 | 1/20 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/21 | 2/20 |
| DiarrheaGastrointestinal disorders | 4/21 | 1/20 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/21 | 2/20 |
| Back painMusculoskeletal and connective tissue disorders | 4/21 | 1/20 |
| InsomniaNervous system disorders | 4/21 | 3/20 |
| RashSkin and subcutaneous tissue disorders | 4/21 | 3/20 |
| Urinary tract infectionInfections and infestations | 2/21 | 3/20 |
| Age, Categorical(Participants) | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 20 | 41 |
| >=65 years | 0 | 1 | 1 |
| Age Continuous(years) | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab | Total |
|---|---|---|---|
| Mean | 46.9 ± 9.6 | 47.4 ± 11.1 | 47.2 ± 10.3 |
| Sex: Female, Male(Participants) | Arm A: 500 mg Rituximab | Arm B: 1000 mg Rituximab | Total |
|---|---|---|---|
| Female | 19 | 18 | 37 |
| Male | 2 | 3 | 5 |
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Methotrexate · Rituximab